An announcement from Virax Biolabs Group Ltd. Class A ( (VRAX) ) is now available.
On March 13, 2025, Virax Biolabs presented data at the World Immune Regulation Meeting in Davos, Switzerland, highlighting the role of T-Cell dysfunction in post-acute infection syndromes (PAIS). The data demonstrated that repeated stimulation of peripheral blood mononuclear cells with SARS-CoV-2 and CMV peptide pools increases T-Cell exhaustion markers, correlating with reduced cytokine production and impaired immune functionality. This research underscores the critical role of T-Cell exhaustion in conditions like long COVID, ME/CFS, and chronic Lyme disease, and supports Virax’s ongoing clinical validation studies to evaluate their T-Cell-based diagnostic’s performance.
More about Virax Biolabs Group Ltd. Class A
Virax Biolabs Group Limited is an innovative biotechnology company focused on the detection of immune responses and diagnosis of viral diseases. The company is developing T-Cell-based test technologies aimed at providing an immunology profiling platform, particularly effective in diagnosing and treating post-viral syndromes such as Long COVID and other chronic conditions linked to immune dysregulation.
YTD Price Performance: -33.44%
Average Trading Volume: 407,131
Technical Sentiment Consensus Rating: Buy
Learn more about VRAX stock on TipRanks’ Stock Analysis page.